DA XU *, XIAOFENG LIU *, LIJUN WANG and BAOCAI XING
|
|
- Sherman Blair
- 5 years ago
- Views:
Transcription
1 ONCOLOGY LETTERS Heptectomy plus djuvnt trnsctheter rteril chemoemboliztion improves the survivl rte of ptients with multicentric occurrence of heptocellulr crcinom DA XU *, XIAOFENG LIU *, LIJUN WANG nd BAOCAI XING Key Lbortory of Crcinogenesis nd Trnsltionl Reserch (Ministry of Eduction/Beijing), Heptopncretobiliry Surgery Deprtment I, Peking University Cncer Hospitl nd Institute, Beijing , P.R. Chin Received September 5, 2017; Accepted June 29, 2018 DOI: /ol Abstrct. The im of the present study ws to evlute the role of heptectomy plus djuvnt trnsctheter rteril chemoemboliztion (TACE) in ptients with multicentric occurrence (MO) or intrheptic metstses (IM) of heptocellulr crcinom (HCC). Ptients with multifocl HCC who underwent heptic resection only (HR) or HR plus djuvnt TACE (HRT) between Jnury 2005 nd December 2015 were divided into MO or IM groups. The ptient chrcteristics nd outcomes were retrospectively nlyzed. A totl of 103 ptients (59 nd 44 in the MO nd IM groups, respectively) were included in the nlysis. The 1, 3 nd 5 yer overll survivl (OS) rtes were 92.7, 76.8 nd 56.8% for the MO group, nd 93.1, 41.6 nd 18.5% for the IM group, respectively (OS, P=0.001), nd the 1, 3 nd 5 yer disese free survivl (DFS) rtes were 84.1, 44.6 nd 40.5% for the MO group nd 51.7, 22.5 nd 15.0% for the IM group, respectively (DFS, P<0.001). In the subgroup nlysis, the overll survivl were significntly better in the MO HRT group compred with those in the MO HR group (P=0.019), which ws lso observed between the IM HRT nd IM HR groups (P=0.132). Furthermore, the 1, 3 nd 5 yer OS demonstrted non significnt differences between ptients with <3 nd 3 tumors in the MO HR group (P=0.300), but significntly reduced OS for ptients with 3 tumors in the IM HR group compred with tht for ptients with <3 tumors (P=0.132). In conclusion, surgicl resection combined with Correspondence to: Professor Boci Xing, Key Lbortory of Crcinogenesis nd Trnsltionl Reserch (Ministry of Eduction/Beijing), Heptopncretobiliry Surgery Deprtment I, Peking University Cncer Hospitl nd Institute, 52 Fucheng Rod, Beijing , P.R. Chin E mil: xingboci88@sin.com * Contributed eqully Key words: heptocellulr crcinom, multicentric occurrence, intrheptic metstses, heptic resection, trnsctheter rteril chemoemboliztion, survivl djuvnt TACE my result in significntly incresed survivl rtes of ptients with MO HCC. Tumor number should not be n bsolute contrdiction to heptectomy in ptients with MO HCC. Introduction Heptocellulr crcinom (HCC) is common mlignncy globlly nd the third most common cuse of cncer ssocited mortlity (1,2). Surgery hs become the primry tretment for HCC, with 5 yer overll survivl (OS) rte of 40 50% (3,4). Furthermore, >50% of ptients with HCC re initilly dignosed with multiple tumors (5), reducing the probbility of receiving successful tretment for cses tht exceed the Brcelon Clinic Liver Cncer (BCLC) stging system for rdicl heptectomy, due to its high recurrence rte following surgery (6,7); however, previous study determined tht not ll ptients with multinodulr HCC of n intermedite stge would experience poor long term survivl following surgicl resection (8). Multiple HCC lesions my originte differently from multicentric occurrence (MO) or intrheptic metstses (IM), which hve dissimilr outcomes (9). The origin of MO HCC is different from the primry lesion, while IM HCC is derived from the primry tumor. A number of methods nd fetures re used to differentite MO HCC from IM HCC, including tumor loction, stellite tumors, growth from portl tumor emboli or histologicl grding (10,11). In previous studies, ptients with MO HCC were reported to hve n improved outcome compred with ptients with IM HCC following heptectomy (12,13); thus, determining the origin of multifocl HCC my benefit the selection of ptients for rdicl surgery. Additionlly, number of studies lso determined tht djuvnt trnsctheter rteril chemoemboliztion (TACE) my be beneficil in prolonging the survivl of ptients with high risk HCC, including those with lrger size, multinodulr tumors nd microvsculr invsion (14 16); however, the current literture does not indicte the type of multifocl HCC tht my benefit from djuvnt TACE. The present study ws conducted to investigte the survivl benefits for ptients with MO HCC or IM HCC who underwent liver resection nd subsequent djuvnt TACE.
2 2 XU et l: SURGERY PLUS TACE FOR MULTIFOCAL HEPATOCELLULAR CARCINOMA Mterils nd methods Selection of ptients. A totl of 871 ptients with pthologiclly confirmed HCC underwent heptectomy between Jnury 2005 nd December 2015 in Heptopncretobiliry Surgery Deprtment I t the Peking University Cncer Hospitl nd Institute (Beijing, Chin). The study design ws pproved by the Ethicl Review Bord Committee of the Beijing Cncer Hospitl nd Institute (Beijing, Chin). A totl of 107 ptients (12.3%) were pthologiclly dignosed with multinodulr HCC. A totl of 4 ptients were excluded. Finlly, 103 ptients were included in the present study, including 89 men nd 14 women, with medin ge of 57 yers (rnge, yers). According to the forementioned clinicopthologicl determintion criteri, 59 cses were included in the MO group nd 44 cses were included in the IM group. In the MO HCC subgroup, 22 ptients received heptic resection (HR) only (MO HR), nd 37 ptients received HR plus djuvnt TACE (HRT) (MO HRT). The pthologicl stge of ech nodulr ws reviewed nd recorded in the resected specimens by two senior pthologists in blinded mnner using the Edmondson Steiner stging method (6). The demogrphic, surgicl, pthologicl nd survivl dt of ll ptients were collected nd nlyzed. The inclusion criterion included the multinodulr lesions being pthologiclly confirmed s HCC. The exclusion criteri included the following: i) Mixed HCC or cholngiocellulr crcinom; ii) emergence of extrheptic metstsis; iii) no R0 resection; nd iv) existence of nother type of primry tumor. Differentition criteri for MO nd IM of multinodulr HCC. A number of studies hve exmined the differences between IM nd MO (10 12,17). The differentition criteri described in the present study re bsed on the Liver Cncer Study Group criteri (Jpnese Society of HCC criteri) (18). IM HCC is defined bsed on the following: i) Tumor cses tht pper to hve developed from or on the bsis of portl tumor emboli; ii) lrge primry tumor with multiple stellite nodules; nd iii) ll tumors re histologiclly similr. MO HCC is defined bsed on the following: i) Ech tumor occurs seprtely in different heptic segment; nd ii) the multiple tumors hve different histologicl grding of well differentited nd modertely or poorly differentited HCC (pthologicl heterogeneity) (10,11,19). Surgery. Tumor cses were confirmed using contrst enhnced computed tomogrphy (CT) or mgnetic resonnce imging with vsculr contrst gents. A number of ptients were lso ssessed using contrst enhnced ultrsonogrphy. Liver function tests were performed prior to the surgery, including tests for lbumin, bilirubin, blood cogultion function nd 15 min indocynine green clernce. Only ptients with well preserved liver function (Child Pugh grde A) nd good performnce sttus, with n estimted residul liver volume >40%, underwent HR. Ptients with heptitis B infection were treted with ntivirl drugs t lest 1 week prior to surgery. Liver trnsections were primrily performed using the clmp method with Peng multifunctionl opertive dissector [Hngzhou Shuyou Medicl Instrument Co., Ltd., Hngzhou, Chin; FDA ctlog no. 510(K), K040780]. An intermittent Pringle mneuver ws used during liver trnsection. Vsculr invsion ws dignosed if vsculr involvement or tumor invsion ws confirmed by imging or pthologicl studies. Heptic resection ws performed using ntomicl liver resection or prtil liver resection. Resection ws considered s mjor when 3 liver segments were removed nd s minor when <3 liver segments or prtil liver prenchym were removed. Postsurgicl outcomes nd follow up. Postsurgicl mortlity ws defined s mortlity within 30 dys of surgery. Grde III or higher dverse events were considered mjor complictions, while Grde I II dverse events were defined s minor complictions. Postsurgicl heptic insufficiency ws defined ccording to the Interntionl Study Group of Liver Surgery consensus (20). Contrst enhnced CT or mgnetic resonnce imging, chest rdiogrphy, liver function tests nd mesurements of serum α fetoprotein levels were performed 4 weeks fter surgery, nd every 3 months therefter. Tumor recurrences were treted with liver resection, rdiofrequency bltion or TACE. Only 13 ptients did not receive the tretment following recurrence due to fst recurrence of the tumor (within 3 months) or severe liver cirrhosis nd liver filure. Adjuvnt TACE. Adjuvnt TACE (2 cycles) ws suggested to ll ptients with multinodulr HCC by the ttending physicin ~4 weeks fter surgery, when the liver function hd recovered. Whether ptients followed the recommendtions of the physicin primrily depended on their socioeconomic sttus or wishes; therefore, djuvnt TACE ws not performed in ll ptients, with those who refused receiving heptic resection only. The Seldinger technique ws performed to plce heptic rteril ctheter into the proper heptic rtery vi the femorl rtery, with the ptient under locl nesthesi. Heptic ngiogrphy or CT ngiogrphy ws performed to detect ny notble tumor stins in the remnnt liver. Oxlipltin (150 mg) nd leucovorin (150 mg) were infused, nd fluorourcil (1,500 mg/m 2 ) ws continuously pumped (for 24 h) through the ctheter. The dosge ws determined by the body surfce re nd underlying liver function. At the 1 month follow up, CT scn ws obtined to determine the effects of TACE. Study endpoints. The primry endpoint of the study ws to evlute 1, 3 nd 5 yer OS nd disese free survivl (DFS) rtes in the IM nd MO groups. The secondry endpoint ws to evlute the OS benefits nd sfety of heptectomy plus postsurgicl djuvnt TACE. The tertiry endpoint ws to identify whether tumor number ws prognostic fctor ffecting the stging nd long term outcomes of multinodulr HCC. Sttisticl nlysis. Continuous vribles re presented s the men ± stndrd devitions or medins with interqurtile rnges, nd discreet vribles re presented s numbers with percentges. Ctegoricl vribles were compred using the χ 2 test, nd continuous vribles were compred using Student's t test or non prmetric Mnn Whitney U test. Survivl rtes were obtined by the Kpln Meier method nd were compred using the log rnk test. OS nd DFS were clculted from the dte of heptectomy to the time of
3 ONCOLOGY LETTERS 3 Figure 1. Study flowchrt. HCC, heptocellulr crcinom; TACE, trnsctheter rteril chemoemboliztion; MO, multicentric occurrence; IM, intrheptic metstses; HR, heptic resection; HRT, HR plus djuvnt TACE. mortlity/recurrence or the lst time of follow up. Vribles tht were sttisticlly significnt in the univrite nlysis (P<0.05) were included in the multivrite nlysis using Cox proportionl hzrds model. All ptients were followed up until mortlity or until June 1, P<0.05 ws considered to indicte sttisticlly significnt difference. The nlysis ws performed using SPSS version 21.0 sttisticl softwre (IBM Corp., Armonk, NY, USA). Results Grouping bsed on clinicopthologicl fetures. The flowchrt for the present study is depicted in Fig. 1. In totl, 107 ptients with multinodulr tumors who underwent liver resection with or without djuvnt TACE were evluted. A totl of 4 ptients were excluded, including 3 ptients with mixed HCC nd 1 ptient who received rdiofrequency therpy prior to tumor resection; subsequently, the tumor ws pthologiclly demonstrted to hve undergone complete necrosis. None of the ptients were lost to follow up, thus 103 ptients were included in the present study, including 89 men nd 14 women, with medin ge of 57 yers (rnge, yers). According to the forementioned clinicopthologicl determintion criteri, 59 cses were included in the MO group nd 44 cses were included in the IM group for further nlysis. Clinicopthologicl nd surgicl fetures of the ptients. For further nlysis, the clinicopthologicl vribles of the two groups were investigted (Tble I). Tumor size (the lrgest tumor in one ptient) (P=0.008), portl tumor emboli (P=0.031), pthologicl heterogeneity (P=0.002), loction of segment nd stellite tumors (P<0.001) differed significntly between the two groups. The surgicl outcomes nd postsurgicl tretments re presented in Tble II. There were no significnt differences in surgicl time, surgicl blood loss or type of surgery between the two groups. Surgicl morbidities, including heptic insufficiency, scites nd biliry fistul, nd the proportion of ptients receiving djuvnt therpy were lso similr between the two groups. Survivl nlysis. The medin durtion of follow up ws 34 months (rnge, months) for the MO group nd 25 months (rnge, 3 49 months) for the IM group. The Kpln Meier survivl curves for the two groups re depicted in Fig. 2. The 1, 3 nd 5 yer OS rtes were 92.7, 76.8 nd 56.8%, respectively, for the MO group, nd 93.1, 41.6 nd 18.5%, respectively, for the IM group (P=0.001; Fig. 2A). The 1, 3 nd 5 yer DFS rtes were 84.1, 44.6 nd 40.5%, respectively, for the MO group, nd 51.7, 22.5 nd 15.0%, respectively, for the IM group (P<0.001; Fig. 2B). There ws significnt difference between the two groups in terms of DFS nd OS. Multivrite Cox proportionl hzrds regression nlyses identified >2 tumors, no djuvnt TACE nd IM HCC s independent prognostic fctors for OS in ptients with multifocl HCC (Tble III). Subgroup nlysis by tretment method. Ptients with multifocl HCC were further clssified ccording to whether
4 4 XU et l: SURGERY PLUS TACE FOR MULTIFOCAL HEPATOCELLULAR CARCINOMA Tble I. Ptient demogrphic nd clinicopthologicl chrcteristics. Chrcteristics MO HCC (n=59) IM HCC (n=44) P vlue Age, yers Men ± SD 57.05± ±10.81 Sex, n (%) Mle 50 (84.7) 39 (88.6) Femle 9 (15.3) 5 (11.4) Albumin, g/l Men ± SD 44.31± ±4.44 Totl bilirubin, µmol/l Medin (IQR) (8.30) (7.95) Pltelet count, x10 9 /l Medin (IQR) 126 (60) 130 (67.75) Prothrombin time, s Medin (IQR) (1.30) (1.15) Liver cirrhosis, n (%) Yes 57 (96.6) 42 (95.5) No 2 (3.4) 2 (4.5) Underlying heptitis, n (%) HBV 50 (84.7) 40 (90.9) HCV 5 (8.5) 0 (0.0) Both 3 (5.1) 2 (4.5) None 1 (1.7) 2 (4.5) Tumor number, n (%) < (88.1) 21 (47.7) >2 7 (11.9) 23 (52.3) Tumor size (lrgest tumor), mm Medin (IQR) 38.0 (38.0) 56.5 (43.0) Tumor size (second lrgest tumor), mm Medin (IQR) 15.0 (20.0) 12.0 (15.0) AFP, ng/ml Medin (IQR) (306.95) (686.17) Microvsculr invsion, n (%) Yes 13 (22.0) 18 (40.9) No 46 (78.0) 26 (59.1) Portl tumor emboli, n (%) Yes 0 (0.0) 4 (9.1) No 59 (100.0) 40 (90.9) Edmonson grde, n I 6 4 II III Pthologicl heterogeneity, n (%) Yes 40 (81.6) 41 (93.2) No 19 (18.4) 3 (6.8) Loction of segment, n (%) <0.001 Sme 10 (16.9) 32 (72.7) Different 49 (83.1) 12 (27.2) Stellite tumors, n (%) <0.001 Yes 58 (98.3) 22 (50.0) No 1 (1.7) 22 (50.0) P<0.05. MO, multicentric occurrence heptocellulr crcinom; IM, intrheptic metstses heptocellulr crcinom; AFP, α fetoprotein; SD, stndrd devition; IQR, interqurtile rnge; HBV, heptitis B virus; HCV, heptitis C virus.
5 ONCOLOGY LETTERS 5 Tble II. Surgicl nd postsurgicl tretment. MO IM Vribles (n=59) (n=44) P vlue Surgicl time, min Men ± SD 167.1± ±8.5 Surgicl blood loss, ml Medin (IQR) 200 (300) 200 (287.5) Type of surgery, n (%) Minor 42 (71.2) 23 (52.3) Mjor 17 (28.8) 21 (47.7) Surgicl morbidities, n (%) 8 (13.55) 8 (18.2) Heptic insufficiency 5 (8.5) 7 (15.9) Biliry fistul 3 (5.1) 1 (2.3) Adjuvnt TACE, n (%) Yes 37 (62.7) 25 (56.8) No 22 (37.3) 19 (43.2) All ptients experienced Clvien Dindo grde I II compliction; no Grde III or higher complictions or postsurgicl mortlity occurred. MO, multicentric occurrence heptocellulr crcinom; IM, intrheptic metstses heptocellulr crcinom; TACE, trnsctheter rteril chemoemboliztion; SD, stndrd devition; IQR, interqurtile rnge. they underwent HR only or HRT. In the MO HCC subgroup, 22 ptients received HR only (MO HR), nd 37 ptients received HRT (MO HRT). The Kpln Meier survivl curves for the ptients re depicted in Fig. 3. The 1, 3 nd 5 yer OS rtes were 97.1, 86.8 nd 73.2%, respectively, for the MO HRT group, nd 85.2, 60.1 nd 28.0%, respectively, for the MO HR group (P=0.019; Fig. 3A), nd there ws significnt difference between the two groups. Multivrite Cox proportionl hzrds regression nlyses identified no djuvnt TACE s n independent prognostic fctor for OS in ptients with MO HCC (Tble IV). In the IM HCC subgroup, 19 ptients received HR only (IM HR), nd 25 ptients received HRT (IM HRT). The 1, 3 nd 5 yer OS rtes were 100.0, 46.6 nd 25.9%, respectively, for the IM HRT group, nd 84.2, 38.3 nd 25.5%, respectively, for the IM HR group (P=0.132; Fig. 3B), with no significnt difference between the two groups. Subgroup nlysis by tumor number. In order to verify whether tumor number is prognostic fctor ffecting the stging nd tretment of multinodulr HCC, the ptients were clssified ccording to whether they hd <3 or 3 tumors (Tble V). The Kpln Meier survivl curves for the ptients re depicted in Fig. 4. In the MO HCC subgroup, 52 ptients hd <3 tumors nd 7 ptients hd 3 tumors. The 1, 3 nd 5 yer OS rtes were 100.0, 60.0 nd 30.0%, respectively, for the MO HCC subgroup with <3 tumors, nd 91.8, 78.7 nd 59.8%, respectively, for the MO HCC subgroup with 3 tumors (P=0.300; Fig. 4A). There ws no significnt difference between the two groups. Additionlly, 21 ptients with IM HCC hd <3 tumors nd 23 ptients with IM HCC hd 3 tumors. The 1, 3 nd 5 yer OS rtes were 95.2, 88.4 nd 25.8%, respectively, for the IM HCC subgroup with <3 tumors, nd 86.5, 52.1 nd 24.3%, respectively, for ptients with 3 tumors (P=0.022; Fig. 4B). There ws significnt difference between the two groups. Discussion Multifocl tumors re common in HCC (21,22). A previous survey demonstrted tht pproximtely hlf of ll ptients with HCC re dignosed with multiple lesions (23). Despite dvnces in resection nd bltion techniques, the recurrence rte following initil tretment remins high, nd the prognosis of ptients with multifocl HCC following surgicl resection is generlly unfvorble (24,25). According to BCLC stging, pllitive tretment, including TACE, in the only pproprite tretment option for the mjority of ptients with multifocl HCC, with medin survivl time of <20 months nd 5 yer survivl rte of 6 20% (26). Currently, it is ccepted tht multifocl HCC my be clssified into two types: IM nd MO (27,28). IM HCC is primrily considered s metsttic lesion from the centrl tumor; therefore, tumor cses re frequently t n dvnced stge, nd the prognosis is generlly unfvorble. By contrst, MO HCC tumors re derived independently from ech other, resulting in n improved prognosis compred with tht of metsttic disese. Therefore, it is importnt to distinguish between these two tumor types. As erly s the 1990s, surgeons distinguished IM HCC from MO HCC primrily using clinicopthologicl fetures (13,17,29). In the present study, ptients were clssified with multifocl HCC ccording to the Jpnese Society of HCC criteri, nd it ws determined tht 57% were ptients with MO HCC, which is similr to the results of previous study (13). Portl tumor emboli, pthologicl heterogeneity, loction of segments nd stellite tumors differed significntly between the two groups, which is consistent with the differentition criteri for IM nd MO. Previously, number of other pproches hve been developed to differentite between these two HCC types, including profiling of integrted heptitis B virus (HBV) DNA by polymerse chin rection nd southern blotting, loss of heterozygosity nlysis of specific microstellite loci nd next genertion sequencing (28,30,31). In previous study, seven cndidte genes with notble differentil expression in 2 ptients were selected nd vlidtion studies were performed using pired tumor/non tumor tissues from 174 ptients with HBV HCC. Subsequently, the expression of threonine nd tyrosine kinse ws identified s novel dverse prognostic fctor of HBV HCC (28). Furthermore, clinicopthologicl fetures re the most convenient method to distinguish between the two types of multifocl HCC. Using this criteri, it ws determined tht ptients with MO HCC hve n improved benefit (5 yer OS rte of 56.8% nd DFS rte of 40.5%) from liver resection compred with tht of ptients with IM HCC (5 yer OS rte of 18.5% nd DFS rte of 15.0%). Multivrite nlyses identified IM HCC s n independent prognostic fctor for OS in ptients with multifocl HCC. Additionlly, surgery for IM nd MO ws not ssocited with incresed surgicl time or blood loss. All surgicl morbidities were Clvien Dindo grde I nd II, indicting tht surgicl resection for multinodulr HCC is sfe tretment option. This result is consistent with tht of previous study (32).
6 6 XU et l: SURGERY PLUS TACE FOR MULTIFOCAL HEPATOCELLULAR CARCINOMA Tble III. Univrite nd multivrite Cox proportionl hzrds regression nlyses of fctors ssocited with overll survivl of ptients (n=103) with multinodulr heptocellulr crcinom. Univrite Multivrite nlysis Fctor P vlue HR (95% CI) P vlue Tumor number (2/>2) < ( ) Tumor size (<50/ 50 mm) AFP (<100/ 100 ng/ml) Microvsculr invsion (no/yes) Portl tumor emboli (no/yes) Liver cirrhosis (no/yes) MO/IM < ( ) Adjuvnt TACE (no/yes) < ( ) P<0.05. TACE, trnsctheter rteril chemoemboliztion; AFP, α fetoprotein; MO, multicentric occurrence heptocellulr crcinom; IM, intrheptic metstses heptocellulr crcinom; HR, hzrd rtio; CI, confidence intervl. Figure 2. (A) OS nd (B) DFS of ptients with MO or IM. (A) P=0.001 nd (B) P<0.001 (log rnk test). OS, overll survivl; DFS, disese free survivl; MO, multicentric occurrence; IM, intrheptic metstses. Figure 3. OS of (A) ptients with MO nd (B) ptients with IM following tretment with HR or HRT. (A) P=0.019 nd (B) P=0.132 (log rnk test). TACE, trnsctheter rterilv chemoemboliztion; MO, multicentric occurrence; IM, intrheptic metstses; HR, heptic resection; HRT, HR plus djuvnt TACE; OS, overll survivl.
7 ONCOLOGY LETTERS 7 Tble IV. Univrite nd multivrite Cox proportionl hzrds regression nlyses of fctors ssocited with overll survivl of ptients (n=59) with multicentric occurrence heptocellulr crcinom. Univrite Multivrite nlysis Fctor P vlue HR (95% CI) P vlue Tumor number (2/>2) Tumor size (<50/ 50 mm) AFP (<100/ 100 ng/ml) Microvsculr invsion (no/yes) Liver cirrhosis (no/yes) Adjuvnt TACE (no/yes) ( ) P<0.05. AFP, α fetoprotein; TACE, trnsctheter rteril chemoemboliztion; HR, hzrd rtio; CI, confidence intervl. Tble V. Subgroup nlysis clssified by tumor number. Tumor number MO (n=59) IM (n=44) P vlue 2 lesions <0.001 >2 lesions lesions lesions lesions lesions 0 1 P<0.05. MO, multicentric occurrence heptocellulr crcinom; IM, intrheptic metstses heptocellulr crcinom. Figure 4. (A) OS of ptients with MO with <3 or 3 tumors following tretment with HRT. (B) DFS of ptients with IM with <3 or 3 tumors following tretment with HRT. (A) P=0.300 nd (B) P=0.022 (log rnk test). HRT, heptic resection plus djuvnt trnsctheter rteril chemoemboliztion; OS, overll survivl; DFS, disese free survivl; MO, multicentric occurrence; IM, intrheptic metstses. Of the ptients with HCC, ~70% experience recurrence within 5 yers; therefore, reducing the rte of postsurgicl recurrence is key fctor in prolonging long term survivl in ptients with HCC (33,34). Currently, the ccepted method for reducing the recurrence rte of cncer following surgery is djuvnt therpy; however, djuvnt TACE therpy is not recommended for HCC following rdicl surgery ccording to the previous guidelines (6,7), s not ll ptients benefit from it. Previously, number of studies indicted tht djuvnt postsurgicl TACE cn reduce the postsurgicl recurrence rte in high risk ptients with HCC (35 38). Although rndomized controlled tril indicted tht postsurgicl djuvnt therpy hd miniml effect on outcomes, it ws probble tht ptients with erly stge HCC were included in the study (39). In the
8 8 XU et l: SURGERY PLUS TACE FOR MULTIFOCAL HEPATOCELLULAR CARCINOMA present study, it ws determined tht djuvnt TACE ws n independent prognostic fctor for OS in ptients with multifocl HCC; however, it remins unknown if the MO nd IM groups cn benefit from djuvnt TACE therpy following surgery. A further subgroup nlysis demonstrted tht postsurgicl djuvnt TACE significntly prolonged long term survivl in ptients with MO HCC; however, OS ws not significntly prolonged in ptients with IM HCC who underwent djuvnt TACE. Bsed on these results, ptients with MO HCC should be ctively treted with djuvnt TACE to mximize the benefit of surgery. By contrst, since the prognosis of ptients with IM HCC ws significntly worse following heptectomy, postsurgicl djuvnt TACE did not result in the sme survivl benefit for ptients with IM HCC s it did for ptients with MO HCC. Thus, djuvnt TACE my be more beneficil for ptients with MO HCC. Until now, the BCLC stging system nd Americn Assocition for the Study of Liver Disese/Europen Assocition for the Study of the Liver guidelines clssified ptients with >3 tumors s stge B (6,7). TACE is recommended for these ptients s the first line tretment; however, in the present study, it ws determined tht the prognosis of ptients with MO HCC with 3 tumors ws not worse compred with tht of ptients with <3 tumors following heptectomy. For the ptients with IM HCC, n incresed tumor number indicted worse prognosis. A previous study demonstrted tht the long term survivl rte of ptients with MO HCC following surgicl resection ws similr to tht of ptients with single lesions (10). Furthermore, nother study indicted tht resection my be the tretment of choice for HCC even if ptients hve >4 tumors (40). It is probble tht single lesions in MO HCC originte independently from ech other with erly stge grding; therefore, even if >3 tumors re present, surgicl resection is suitble for these ptients. However, the lesions re metstses from one lesion in IM HCC, which re similr to distnt metstsis; therefore, n incresed number of tumors is indictive of lter stge. Although the study smple ws smll, the present results indicted tht HCC stging should not rely on tumor sttus lone, nd tht IM nd MO crcinogenesis should lso be tken into ccount. Furthermore, tumor number should not be the primry fctor considered when selecting the MO HCC tretment. There re number of limittions to the present study. Firstly, since multinodulr HCC with >3 tumors or with 2 tumors, 1 of which is >3 cm, re clssified s BCLC stge B, it ws controversil to perform surgery. Thus, limited number of these ptients were included in the study, lthough no less thn the number included in previous studies (12,13). Lrger cohort studies my be necessry to confirm the results. Secondly, the ptients included in the present study were ptients with HCC in Chin, nd 92.2% of ptients hd HBV ssocited HCC. In western countries, the most common cuses of HCC re heptitis C nd lcohol (6). The different etiologies my cuse HCC origin differences, nd thus ffect the rtio of IM nd MO. To confirm the conclusions of the present study, further multicenter perspective studies should be performed with lrger cohort. In conclusion, the present dt demonstrted tht ptients with MO HCC benefit from HRT, while the sme tretment hs miniml effect on the survivl of ptients with IM HCC. Accordingly, liver resection plus TACE is recommended for MO HCC, nd TACE, trgeted drugs or other pllitive tretment should be considered for IM HCC. Prospective multicenter studies with lrger smple re required in the future to further confirm the present results. Acknowledgements Not pplicble. Funding This study ws funded by grnts from the Chinese Stte Key Project for Bsic Reserch (973) (no. 2014CBA02001). Avilbility of dt nd mterils The dtsets used or nlyzed during the current study re vilble from the corresponding uthor on resonble request. Authors' contributions DX, XL nd BX prticipted in the design of the study. DX nd LW collected the dt. DX nd XL nlyzed nd interpreted the dt. DX, XL nd BX prepred the mnuscript. All uthors red nd pproved the finl mnuscript. Ethics pprovl nd consent to prticipte The study ws pproved by the Ethics Committee of Beijing Cncer Hospitl. Ptient consent for publiction Informed consent sttement: Ptients were not required to give informed consent to the study, s the nlysis used nonymous clinicl dt tht were obtined fter ech ptient greed to tretment by verbl consent. Individuls cnnot be identified ccording to the dt presented. Competing interests The uthors declre tht they hve no competing interests. References 1. Mluccio M nd Covey A: Recent progress in understnding, dignosing, nd treting heptocellulr crcinom. CA Cncer J Clin 62: , Jeml A, Bry F, Center MM, Ferly J, Wrd E nd Formn D: Globl cncer sttistics. CA Cncer J Clin 61: 69 90, Zhong JH, Ke Y, Gong WF, Xing BD, M L, Ye XP, Peng T, Xie GS nd Li LQ: Heptic resection ssocited with good survivl for selected ptients with intermedite nd dvnced stge heptocellulr crcinom. Ann Surg 260: , Torzilli G, Belghiti J, Kokudo N, Tkym T, Cpussotti L, Nuzzo G, Vuthey JN, Choti MA, De Sntibnes E, Dondon M, et l: A snpshot of the effective indictions nd results of surgery for heptocellulr crcinom in tertiry referrl centers: Is it dherent to the EASL/AASLD recommendtions?: An observtionl study of the HCC Est West study group. Ann Surg 257: , 2013.
9 ONCOLOGY LETTERS 9 5. Hsu CY, Liu PH, Hsi CY, Lee YH, Ngri TS, Lee RC, Lin HC nd Huo TI: Surgicl resection is better thn trnsrteril chemoemboliztion for ptients with heptocellulr crcinom beyond the miln criteri: A prognostic nomogrm study. Ann Surg Oncol 23: , Europen Assocition For The Study Of The Liver; Europen Orgnistion For Reserch And Tretment Of Cncer: EASL EORTC clinicl prctice guidelines: Mngement of heptocellulr crcinom. J Heptol 56: , Bruix J nd Shermn M; Americn Assocition for the Study of Liver Diseses: Mngement of heptocellulr crcinom: An updte. Heptology 53: , Kudo M, Izumi N, Kokudo N, Mtsui O, Skmoto M, Nkshim O, Kojiro M nd Mkuuchi M; HCC Expert Pnel of Jpn Society of Heptology: Mngement of heptocellulr crcinom in Jpn: Consensus bsed clinicl prctice guidelines proposed by the Jpn society of heptology (JSH) 2010 updted version. Dig Dis 29: , Feo F nd Pscle RM: Multifocl heptocellulr crcinom: Intrheptic metstsis or multicentric crcinogenesis? Ann Trnsl Med 3: 4, Ysui M, Hrd A, Nonmi T, Tkeuchi Y, Tniguchi K, Nko A nd Tkgi H: Potentilly multicentric heptocellulr crcinom: Clinicopthologic chrcteristics nd postopertive prognosis. World J Surg 21: , Shimd M, Hmtsu T, Ymshit Y, Rikimru T, Tguchi K, Utsunomiy T, Shirbe K nd Sugimchi K: Chrcteristics of multicentric heptocellulr crcinoms: Comprison with intrheptic metstsis. World J Surg 25: , Wng J, Li Q, Sun Y, Zheng H, Cui Y, Li H, Zhou H nd Ho X: Clinicopthologic fetures between multicentric occurence nd intrheptic metstsis of multiple heptocellulr crcinoms relted to HBV. Surg Oncol 18: 25 30, Li SL, Su M, Peng T, Xio KY, Shng LM, Xu BH, Su ZX, Ye XP, Peng N, Qin QL, et l: Clinicopthologic chrcteristics nd prognoses for multicentric occurrence nd intrheptic metstsis in synchronous multinodulr heptocellulr crcinom ptients. Asin Pc J Cncer Prev 14: , Sun JJ, Wng K, Zhng CZ, Guo WX, Shi J, Cong WM, Wu MC, Lu WY nd Cheng SQ: Postopertive djuvnt trnsctheter rteril chemoemboliztion fter R0 heptectomy improves outcomes of ptients who hve heptocellulr crcinom with microvsculr invsion. Ann Surg Oncol 23: , Dong ZR, Zhng PF, Wng CH, Zhng C, Ci JB, Shi GM, Ke AW, Sun HC, Qiu SJ, Zhou J nd Fn J: Postopertive djuvnt trnsctheter rteril chemoemboliztion for resectble multiple heptocellulr crcinom beyond the Miln criteri: A retrospective nlysis. Am J Cncer Res 5: , Liu C, Sun L, Xu J nd Zho Y: Clinicl efficcy of postopertive djuvnt trnsctheter rteril chemoemboliztion on heptocellulr crcinom. World J Surg Oncol 14: 100, Tkenk K, Adchi E, Nishizki T, Hiroshige K, Iked T, Tsuneyoshi M nd Sugimchi K: Possible multicentric occurrence of heptocellulr crcinom: A clinicopthologicl study. Heptology 19: , Liver Cncer Study Group of Jpn: Primry liver cncer in Jpn. Clinicopthologic fetures nd results of surgicl tretment. Ann Surg 211: , Mtsumoto Y, Fujii H, Mtsud M nd Kono H: Multicentric occurrence of heptocellulr crcinom: Dignosis nd clinicl significnce. J Heptobiliry Pncret Surg 8: , Rhbri NN, Grden OJ, Pdbury R, Brooke Smith M, Crwford M, Adm R, Koch M, Mkuuchi M, Demtteo RP, Christophi C, et l: Postheptectomy liver filure: A definition nd grding by the Interntionl Study Group of Liver Surgery (ISGLS). Surgery 149: , Oikw T, Ojim H, Ymski S, Tkym T, Hirohshi S nd Skmoto M: Multistep nd multicentric development of heptocellulr crcinom: Histologicl nlysis of 980 resected nodules. J Heptol 42: , Ng IO, Gun XY, Poon RT, Fn ST nd Lee JM: Determintion of the moleculr reltionship between multiple tumour nodules in heptocellulr crcinom differentites multicentric origin from intrheptic metstsis. J Pthol 199: , Chn AC, Chn SC, Chok KS, Cheung TT, Chiu DW, Poon RT, Fn ST nd Lo CM: Tretment strtegy for recurrent heptocellulr crcinom: Slvge trnsplnttion, repeted resection, or rdiofrequency bltion? Liver Trnspl 19: , Gluer AM, Cocco N, Lurence JM, Johnston ES, Hollnds MJ, Pless HC, Richrdson AJ nd Lm VW: Systemtic review of ctul 10 yer survivl following resection for heptocellulr crcinom. HPB (Oxford) 14: , Hsegw K, Kokudo N, Mkuuchi M, Izumi N, Ichid T, Kudo M, Ku Y, Skmoto M, Nkshim O, Mtsui O nd Mtsuym Y: Comprison of resection nd bltion for heptocellulr crcinom: A cohort study bsed on Jpnese ntionwide survey. J Heptol 58: , Bolondi L, Burroughs A, Dufour JF, Glle PR, Mzzferro V, Piscgli F, Roul JL nd Sngro B: Heterogeneity of ptients with intermedite (BCLC B) Heptocellulr Crcinom: Proposl for subclssifiction to fcilitte tretment decisions. Semin Liver Dis 32: , Xue R, Li R, Guo H, Guo L, Su Z, Ni X, Qi L, Zhng T, Li Q, Zhng Z, et l: Vrible intr tumor genomic heterogeneity of multiple lesions in ptients with heptocellulr crcinom. Gstroenterology 150: , Mio R, Luo H, Zhou H, Li G, Bu D, Yng X, Zho X, Zhng H, Liu S, Zhong Y, et l: Identifiction of prognostic biomrkers in heptitis B virus relted heptocellulr crcinom nd strtifiction by integrtive multi omics nlysis. J Heptol 61: , Kumd T, Nkno S, Tked I, Sugiym K, Osd T, Kiriym S, Sone Y, Toyod H, Shimd S, Tkhshi M nd Sss T: Ptterns of recurrence fter initil tretment in ptients with smll heptocellulr crcinom. Heptology 25: 87 92, Ymmoto T, Kjino K, Kudo M, Sski Y, Arkw Y nd Hino O: Determintion of the clonl origin of multiple humn heptocellulr crcinoms by cloning nd polymerse chin rection of the integrted heptitis B virus DNA. Heptology 29: , Morimoto O, Ngno H, Skon M, Fujiwr Y, Ymd T, Nkgw H, Miymoto A, Kondo M, Ari I, Ymmoto T, et l: Dignosis of intrheptic metstsis nd multicentric crcinogenesis by microstellite loss of heterozygosity in ptients with multiple nd recurrent heptocellulr crcinoms. J Heptol 39: , Kim PT, Jng JH, Atenfu EG, Fischer S, Greig PD, McGilvry ID, Wei AC, Gllinger S nd Clery SP: Outcomes fter heptic resection nd subsequent multimodl tretment of recurrence for multifocl heptocellulr crcinom. Br J Surg 100: , Tur K, Iki I, Htno E, Fujii H, Uym N nd Shimhr Y: Impliction of frequent locl bltion therpy for intrheptic recurrence in prolonged survivl of ptients with heptocellulr crcinom undergoing heptic resection: An nlysis of 610 ptients over 16 yers old. Ann Surg 244: , Poon RT, Fn ST, Lo CM, Ng IO, Liu CL, Lm CM nd Wong J: Improving survivl results fter resection of heptocellulr crcinom: A prospective study of 377 ptients over 10 yers. Ann Surg 234: 63 70, Llovet JM nd Bruix J: Systemtic review of rndomized trils for unresectble heptocellulr crcinom: Chemoemboliztion improves survivl. Heptology 37: , Llovet JM, Rel MI, Montn X, Plns R, Coll S, Aponte J, Ayuso C, Sl M, Muchrt J, Solà R, et l: Arteril embolistion or chemoembolistion versus symptomtic tretment in ptients with unresectble heptocellulr crcinom: A rndomised controlled tril. Lncet 359: , Lo CM, Ngn H, Tso WK, Liu CL, Lm CM, Poon RT, Fn ST nd Wong J: Rndomized controlled tril of trnsrteril lipiodol chemoemboliztion for unresectble heptocellulr crcinom. Heptology 35: , Cheng X, Sun P, Hu QG, Song ZF, Xiong J nd Zheng QC: Trnsrteril (chemo)emboliztion for curtive resection of heptocellulr crcinom: A systemtic review nd met nlyses. J Cncer Res Clin Oncol 140: , Yin L, Li H, Li AJ, Lu WY, Pn ZY, Li EC, Wu MC nd Zhou WP: Prtil heptectomy vs. trnsctheter rteril chemoemboliztion for resectble multiple heptocellulr crcinom beyond Miln Criteri: A RCT. J Heptol 61: 82 88, Nojiri K, Tnk K, Tked K, Ued M, Mtsuym R, Tniguchi K, Kummoto T, Mori R nd Endo I: The efficcy of liver resection for multinodulr heptocellulr crcinom. Anticncer Res 34: , This work is licensed under Cretive Commons Attribution-NonCommercil-NoDerivtives 4.0 Interntionl (CC BY-NC-ND 4.0) License.
Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationSystematic review of actual 10-year survival following resection for hepatocellular carcinoma
DOI:10.1111/j.1477-2574.2012.00446.x HPB SYSTEMATIC REVIEW Systemtic review of ctul 10-yer survivl following resection for heptocellulr crcinom Annelise M. Gluer 1, Nichols Cocco 1, Jerome M. Lurence 1,2,
More informationCase Report INTRODUCTION CASE REPORT. pissn eissn X
pissn 2287-2728 eissn 2287-285X Cse Report Clinicl nd Moleculr Heptology 2018;24:424-429 Complete cure of dvnced heptocellulr crcinom with right drenl glnd metstsis nd portl vein thrombosis by multiple
More informationImpact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors
Originl Article Impct of Positive Nodl Metstses in Ptients with Thymic Crcinom nd Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, nd Jennifer L. Sullivn, MD Introduction: Thymic crcinoms
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationImproved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study
Journl of Heptology 37 (2002) 78 86 www.elsevier.com/locte/jhep Improved prognosis of postopertive heptocellulr crcinom ptients when treted with functionl foods: prospective cohort study Yoichi Mtsui*,
More informationFactors affecting screening for hepatocellular carcinoma
204 Al Hsni F, et l., 2014; 13 (2): 204-210 ORIGINAL ARTICLE Mrch-April, Vol. 13 No. 2, 2014: 204-210 Fctors ffecting screening for heptocellulr crcinom Frh Al Hsni,* Mrin Knoepfli, Armin Gemperli, Attil
More informationPrognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic
Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationClinical manifestations in patients with alpha-fetoprotein producing gastric cancer
Curr Oncol, Vol. 21, pp. e394-399; doi: http://dx.doi.org/10.3747/co.21.1768 CLINICAL MANIFESTATIONS IN AFP PRODUCING GASTRIC CANCER ORIGINAL ARTICLE Clinicl mnifesttions in ptients with lph-fetoprotein
More informationEsophageal carcinoma is the eighth most common cancer
ORIGINAL ARTICLE Tumor-Strom Rtio Is n Independent Predictor for Survivl in Esophgel Squmous Cell Crcinom Ki Wng, MD,* Wei M, MD,* Jinbo Wng, MD,* Ling Yu, MD, Xiomei Zhng, MD, Zhenbo Wng, MD, Bingxu Tn,
More informationAsian Journal of Andrology (2017) 19,
(2017) 19, 20 25 2017 AJA, SIMM & SJTU. All rights reserved 1008-682X www.sindro.com; www.jndrology.com Prostte Cncer Open Access ORIGINAL ARTICLE Refining the Americn Urologicl Assocition nd Americn Society
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationClinicopathological analysis and prognosis of extrahepatic bile duct cancer with a microscopic positive ductal margin
DOI:10.1111/hpb.12193 HPB ORIGINAL ARTICLE Clinicopthologicl nlysis nd prognosis of extrheptic bile duct cncer with microscopic positive ductl mrgin In Woong Hn 1 *, Jin-Young Jng 2 *, Kyoung Bun Lee 3,
More informationAge related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer
MOLECULAR AND CLINICAL ONCOLOGY 9: 329-334, 2018 Age relted differences in prognosis nd prognostic fctors mong ptients with epithelil ovrin cncer KENJI YOSHIKAWA, TAKESHI FUKUDA, RYO UEMURA, HIROAKI MATSUBARA,
More informationLung cancer is the leading cause of cancer death worldwide, EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Originl Article EGFR Muttion nd Brin Metstsis in Pulmonry Adenocrcinoms Dong-Yeop Shin, MD,* Im Il N, MD,* Cheol Hyeon Kim, MD, PhD, Sunhoo Prk, MD, PhD, HeeJong Bek, MD, PhD, nd Sung Hyun Yng, MD, PhD*
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationAmerican Joint Committee on Cancer Staging and Clinicopathological High-Risk Predictors of Ocular Surface Squamous Neoplasia
Americn Joint Committee on Cncer Stging nd Clinicopthologicl High-Risk Predictors of Oculr Surfce Squmous Neoplsi A Study From Tertiry Eye Center in Indi Sheetl Chuhn, MSc; Seem Sen, MD; Anjn Shrm, PhD;
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationOne of the most important biological mechanisms of
Brief Report Serum Thymidine Kinse 1 Activity in the Prognosis nd Monitoring of Chemotherpy in Lung Cncer Ptients: A Brief Report Benjmin Nismn, PhD,* Hovv Nechushtn, MD, PhD,* Him Birn, MD, Hds Gntz-Sorotsky,
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationClassic Papillary Thyroid Carcinoma with Tall Cell Features and Tall Cell Variant Have Similar Clinicopathologic Features
The Koren Journl of Pthology 2014; 48: 201-208 ORIGINAL ARTICLE Clssic Ppillry Thyroid Crcinom with Tll Cell Fetures nd Tll Cell Vrint Hve Similr Clinicopthologic Fetures Woo Jin Oh 1 Young Sub Lee 1 Uiju
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationProphylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications
Gstric Cncer (2018) 21:703 709 https://doi.org/10.1007/s10120-017-0781-y ORIGINAL ARTICLE Prophylctic effect of neodjuvnt chemotherpy in gstric cncer ptients with postopertive complictions Kojiro Eto 1
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationPatient Survival After Surgical Treatment of Rectal Cancer
Originl Article Ptient Survivl After Surgicl Tretment of Rectl Cncer Impct of Surgeon nd Hospitl Chrcteristics Dvid A. Etzioni, MD, MSHS 1,2 ; Toni M. Young-Fdok, MD, MS 1 ; Robert R. Cim, MD, MA 2,3 ;
More informationOriginal Article. Breast Care 2016;11: DOI: /
Originl Article Brest Cre 2016;11:323 327 DOI: 10.1159/000452079 Published online: October 24, 2016 Neodjuvnt Chemotherpy with Docetxel, Crbopltin nd Weekly Trstuzumb Is Active in HER2-Positive Erly Brest
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationAssociation between LAPTM4B gene polymorphism and susceptibility to and prognosis of diffuse large B cell lymphoma
264 Assocition between LAPTM4B gene polymorphism nd susceptibility to nd prognosis of diffuse lrge B cell lymphom HUIRONG DING 1*, XIAOJING CHENG 2*, NING DING 3*, ZHIHUA TIAN 1, JUN ZHU 3, CHUNLIAN ZHOU
More informationMOLECULAR AND CLINICAL ONCOLOGY 7: , 2017
MOLECULAR AND CLINICAL ONCOLOGY 7: 787-797, 2017 Evlution of epiderml growth fctor receptor serum levels nd their ssocition with clinicopthologicl chrcteristics in ptients with colorectl cncer MEHMET KARABULUT
More informationBiliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan
J Heptoiliry Pncret Surg (2009) 16:1 7 DOI 10.1007/s00534-008-0015-0 TOPICS Biliry trct cncer sttistics registry in Jpn Biliry trct cncer tretment: 5,584 results from the Biliry Trct Cncer Sttistics Registry
More informationP (RCC) was first done in the late 1930s and reported in
Pulmonry Resection of Metsttic Renl Cell Crcinom Robert J. Cerfolio, MD, Mrk S. Allen, MD, Clude Deschmps, MD, Richrd C. Dly, MD, Steven L. Wllrichs, BS, Victor F. Trstek, MD, nd Peter C. Pirolero, MD
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationTumor Vascularity Does Not Predict Response to Yttrium-90 Radioembolization for Hepatic Metastases from Colorectal Cancer
Originl Article 3 Tumor Vsculrity Does Not Predict Response to Yttrium-90 Rdioemboliztion for Heptic Metstses from Colorectl Cncer Alipi V. Nydenov Willim P. Hrris 2 Guy E. Johnson 3 Dniel S. Hippe 4 Siddhrth
More informationThe Acute Time Course of Concurrent Activation Potentiation
Mrquette University e-publictions@mrquette Exercise Science Fculty Reserch nd Publictions Exercise Science, Deprtment of 1-1-2010 The Acute Time Course of Concurrent Activtion Potentition Luke Grceu Mrquette
More informationRheumatoid-susceptible alleles of HLA-DRB 1 are genetically recessive to non-susceptible alleles in the progression of bone destruction in the wrists
Annls of the Rheumtic Diseses 1994; 53: 587-592 587 Deprtment of Orthopedic Surgery, Knsi Medicl University, Otokoym Hospitl, Kyoto, Jpn Y Tod Y Mori Deprtment of Orthopedic Surgery, Knsi Medicl University,
More informationSignificance of Expression of TGF- in Pulmonary Metastasis in Non-small Cell Lung Cancer Tissues
Originl Article Significnce of Expression of in Pulmonry Metstsis in Non-smll Cell Lung Cncer Tissues Hisshi Sji, Hruhiko Nkmur, Idiris Awut, Norihito Kwski, Msru Hgiwr, Akihiko Ogt, Mkoto Hosk, Tkmoto
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationCorrelation between CT features and liver function and p53 expression in hepatitis, cirrhosis and hepatocellular carcinoma
ONCOLOGY LETTERS Correltion between CT fetures nd liver function nd p53 expression in heptitis, cirrhosis nd heptocellulr crcinom YAHUI HU, JING WU, SHA LI nd XIAOXIAO ZHAO Deprtment of Nucler Medicine,
More informationAdjuvant chemotherapy for colon carcinoma with positive lymph nodes: use and benefit in routine health care practice
doi: 10.1054/ bjoc.2001.2035, vilble online t http://www.idelibrry.com on http://www.bjcncer.com Adjuvnt chemotherpy for colon crcinom with positive lymph nodes: use nd benefit in routine helth cre prctice
More informationSupplementary Online Content
Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationBreast-Conserving Surgery Under Local Anesthesia in Elderly Patients with Severe Cardiorespiratory Comorbidities: A Hospital-Based Case-Control Study
Originl Article Brest Cre 2017;12:29 33 DOI: 10.1159/000455003 Published online: Februry 8, 2017 Brest-Conserving Surgery Under Locl in Elderly Ptients with Severe Crdiorespirtory Comorbidities: A Hospitl-Bsed
More informationAssociation of PTEN expression with liver function and inflammatory changes in patients with liver cancer after chemotherapy
ONCOLOGY LETTERS Assocition of PTEN expression with liver function nd inflmmtory chnges in ptients with liver cncer fter chemotherpy JIXIANG ZHOU nd XIAOLI LI Deprtment of Heptobiliry Surgery, Xingy Hospitl,
More informationRESEARCH ARTICLE. Wen Li 1, Jing Deng 2 *, Shuang-Shuang Wang 1, Liang Ma 1, Jiang Pei 1, Xiao-Xi Zeng 1, Jian-Xin Tang 1. Abstract.
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.24.10937 Methyltion of the RAR-β Gene nd Cigrette Smoking in NSCLC in Southern-Centrl Chinese RESEARCH ARTICLE Assocition of Methyltion of the RAR-β Gene with
More informationA retrospective, single center cohort study on 65 patients with primary retroperitoneal liposarcoma
ONCOLOGY LETTERS 15: 1799-1810, 2018 A retrospective, single center cohort study on 65 ptients with primry retroperitonel liposrcom YI XI WU 1, JUN YAN LIU 1*, JIA JIA LIU 1*, PENG YAN 1, BO TANG 1, YOU
More informationMOLECULAR AND CLINICAL ONCOLOGY 5: , 2016
MOLECULAR AND CLINICAL ONCOLOGY 5: 429-436, 2016 Improvement of survivl with postmstectomy rdiotherpy in ptients with 1-3 positive xillry lymph nodes: A systemtic review nd met-nlysis of the current literture
More informationThe burden of cirrhosis and impact of universal coverage public health care system in Thailand: Nationwide study
862 Poovorwn K, et l., 2015; 14 (6): 862-868 ORIGINAL ARTICLE November-December, Vol. 14 No. 6, 2015: 862-868 The burden of cirrhosis nd impct of universl coverge public helth cre system in Thilnd: Ntionwide
More informationMOLECULAR AND CLINICAL ONCOLOGY 7: , 2017
336 Effect of intrtumorl bscess/necrosis on the outcome for hed nd neck cncer ptients treted by hypofrctionted stereotctic re irrdition using CyberKnife HIDEYA YAMAZAKI 1,2, MIKIO OGITA 3, KENGO HIMEI
More informationRelation of Tumor Size, Lymph Node Status, and Survival in
Reltion of Tumor Size, Lymph Node Sttus, nd Survivl in 24,74 Brest Cncer Cses CHRISTINE L. CARTER, PHD, MPH,* CAROL ALLEN, PHD,t AND DONALD E. HENSON, MD* Two of the most importnt prognostic indictors
More informationOlanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study
Originl Article Olnzpine for the prophylxis nd rescue of chemotherpyinduced nuse nd vomiting (CINV): retrospective study Leonrd Chiu, Nichols Chiu, Ronld Chow, Liying Zhng, Mrk Psetk, Jordn Stinson, Brenne
More informationAnalysis of Risk Factors for the Development of Incisional and Parastomal Hernias in Patients after Colorectal Surgery
Originl Article Journl of the Koren Society of J Koren Soc Coloproctol 2012;28(6):299-303 http://dx.doi.org/10.3393/jksc.2012.28.6.299 pissn 2093-7822 eissn 2093-7830 Anlysis of Risk Fctors for the Development
More informationphosphatase isoenzyme activity: estimation of
J Clin Pthol 1988;41:202-206 Quntittive method for determining serum lkline phosphtse isoenzyme ctivity: estimtion of intestinl component M J PEAKE, M PEJAKOVIC, G H WHITE From the Deprtment ofbiochemistry
More informationClinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population
Originl Article Clinicl sttistics nlysis on the chrcteristics of pneumoconiosis of Chinese miner popultion Mei-Fng Wng 1 *, Run-Ze Li 2 *, Ying Li 2, Xue-Qin Cheng 1, Jun Yng 1, Wen Chen 3, Xing-Xing Fn
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationMetformin and breast cancer stage at diagnosis: a population-based study
ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationOriginal Article Serum tumor markers used for predicting esophagogastric junction adenocarcinoma in esophageal malignancy
Int J Clin Exp Med 2016;9(6):11859-11864 www.ijcem.com /ISSN:1940-5901/IJCEM0025330 Originl Article Serum tumor mrkers used for predicting esophgogstric junction denocrcinom in esophgel mlignncy Yongkng
More informationR Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1
Bone Mrrow Trnsplnttion, (1999) 24, 283 287 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of the clssic Glucksberg criteri nd the IBMTR Severity
More informationNeutrophil lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors
2454 Neutrophil lymphocyte rtio predicts survivl in pncretic neuroendocrine tumors GUOPEI LUO 1 3*, CHEN LIU 1 3*, HE CHENG 1 3*, KAIZHOU JIN 1 3, MENG GUO 1 3, YU LU 1 3, JIANG LONG 1 3, JIN XU 1 3, QUANXING
More informationCHEST. Thyroid transcription factor 1 (TTF-1) is an important. Original Research
CHEST Originl Reserch Clinicl Significnce of Thyroid Trnscription Fctor-1 in Advnced Lung Adenocrcinom Under Epiderml Growth Fctor Receptor Tyrosine Kinse Inhibitor Tretment Kuei-Pin Chung, MD; Yen-Tsung
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationHigh EGFR mrna expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy
INTERNATIONAL JOURNAL OF ONCOLOGY 38: 629-641, 2011 High EGFR mrna expression is prognostic fctor for reduced survivl in pncretic cncer fter gemcitbine-bsed djuvnt chemotherpy Hyto Fujit 1, Kenoki Ohuchid
More informationThe potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens
The potentil future of trgeted rdionuclide therpy: implictions for occuptionl exposure? Introduction: Trgeted Rdionuclide Therpy (TRT) Systemic tretment Molecule lbelled with rdionuclide delivers toxic
More informationCME/SAM. Study on Hyperuricemia in HBV-Associated Glomerulonephritis
AJCP / Originl Article Study on Hyperuricemi in HBV-Associted Glomerulonephritis Yongze Zhung, MD, PhD, 1 Yingho Yu, MD, PhD, 2 Yingfng Hung, MD, 3 nd Xiorong Zhong, MD 1 From the 1 Deprtment of Nephrology,
More informationOsteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes
ONCOLOGY LETTERS Osteosrcom in ptients below 25 yers of ge: An observtionl study of incidence, metstsis, tretment nd outcomes ZHIGANG NIE nd HAO PENG Deprtment of Orthopedics, Renmin Hospitl of Wuhn University,
More informationInhaled Corticosteroid Is Associated With an Increased Risk of TB in Patients With COPD
CHEST Originl Reserch Inhled Corticosteroid Is Associted With n Incresed Risk of TB in Ptients With COPD Jung-Hyun Kim, MD ; Ji-Soo Prk, MD ; Kyung-Ho Kim, MD ; Hye-Cheol Jeong, MD ; Eun-Kyung Kim, MD
More informationEffects of modified FOLFOX-6 chemotherapy on cellular immune function in patients with gastric cancer
ONCOLOGY LETTERS 15: 8635-8640, 2018 Effects of modified FOLFOX-6 chemotherpy on cellulr immune function in ptients with gstric cncer LIANG WANG 1, DONGER ZHOU 1, HAITAO REN 2 nd YAN CHEN 3 Deprtments
More informationThe Role of Intraoperative Radiation Therapy (IORT) in the Treatment of Locally Advanced Gynecologic Malignancies
The Role of Intropertive Rdition Therpy (IORT) in the Tretment of Loclly Advnced Gynecologic Mlignncies MARCELA G. DEL CARMEN, JAMES F. MCINTYRE, b ANNEKATHRYN GOODMAN Vincent Gynecologic Oncology Service,
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More information8/1/2017. Correlating Radiomics Information with Clinical Outcomes for Lung SBRT. Disclosure. Acknowledgements
Correlting Rdiomics Informtion with Clinicl Outcomes for Lung SBRT Fng-Fng Yin, PhD Duke University Medicl Center AAPM 2017 Denver CO Disclosure This reserch is prtilly funded by reserch grnt from Vrin
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationLung cancer is the leading cause of cancer-related deaths in
ORIGINAL ARTICLE Resection Rte nd Outcome of Pulmonry Resections for Non Smll-Cell Lung Cncer A Ntionwide Study From Icelnd Hunbogi Thorsteinsson, MD,* Asgeir Alexndersson, MD,* Gudrun N. Oskrsdottir,
More informationORIGINAL ARTICLE ABSTRACT INTRODUCTION
ORIGINAL ARTICLE LOSS OF EPCAM STAINING CORRELATES WITH POOR OUTCOME IN CRC, Wng et l. Reduction in membrnous immunohistochemicl stining for the intrcellulr domin of epithelil cell dhesion molecule correltes
More informationRisks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria
Clinicl Prctice: Mini-Review Received: My 20, 2016 Accepted fter revision: December 14, 2016 Published online: Jnury 27, 2017 Risks for All-Cuse Mortlity: Strtified by Age, Estimted Glomerulr Filtrtion
More informationPrognostic factors in tongue cancer relative importance of demographic, clinical and histopathological factors
British Journl of Cncer (2000) 83(5), 614 619 doi: 10.1054/ bjoc.2000.1323, vilble online t http://www.idelibrry.com on Prognostic fctors in tongue cncer reltive importnce of demogrphic, clinicl nd histopthologicl
More informationA cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis
Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu
More informationAnalysis of Regulatory of Interrelated Activity of Hepatocyte and Hepatitis B Viruses
Interntionl Journl of Biomedicl Mterils Reserch 8 6(): -7 http://www.sciencepublishinggroup.com/j/ijbmr doi:.648/j.ijbmr.86. ISSN: 33-756 (Print) ISSN: 33-7579 (Online) Anlysis of Regultory of Interrelted
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationSUPPLEMENTARY INFORMATION
Prentl doi:.8/nture57 Figure S HPMECs LM Cells Cell lines VEGF (ng/ml) Prentl 7. +/-. LM 7. +/-.99 LM 7. +/-.99 Fold COX induction 5 VEGF: - + + + Bevcizum: - - 5 (µg/ml) Reltive MMP LM mock COX MMP LM+
More informationDepartment of Surgery, Central Hospital of Central Finland, Jyväskylä, Finland 2
557016SJS0010.1177/1457496914557016Fst-trck colorectl surgerya. Ehrlich, et l. reserch-rticle2014 ORIGINAL ARTICLE Comprison of lproscopic nd colonic resection within fst-trck nd trditionl periopertive
More informationEffect of Preoperative Intravenous Methocarbamol and Intravenous Acetaminophen on Opioid Use After Primary Total Hip and Knee Replacement
Feture Article Effect of Preopertive Intrvenous Methocrbmol nd Intrvenous Acetminophen on Opioid Use After Primry Totl Hip nd Knee Replcement THOMAS D. LOOKE, MD, PHD; CAMERON T. KLUTH, MBA bstrct Between
More informationRisk of Colorectal Cancer by Subsite in a Swedish Prostate Cancer Cohort
Specil Report Risk of Colorectl Cncer by Subsite in Swedish Prostte Cncer Cohort Yunxi Lu, MD, PhD, Rickrd Ljung, MD, PhD, Ann Mrtling, MD, PhD, nd Mts Lindbld, MD, PhD Bckground: The reltionship between
More informationAssessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II
Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)
More informationOriginal Article Prognostic and clinicopathologic significance of AEG-1/MTDH and E-cadherin expression in human gallbladder carcinoma
Int J Clin Exp Pthol 2018;11(12):6025-6031 www.ijcep.com /ISSN:1936-2625/IJCEP0086349 Originl Article Prognostic nd clinicopthologic significnce of AEG-1/MTDH nd E-cdherin expression in humn gllbldder
More informationkey words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous
reserch report Effect of Route of Bortezomib Administrtion on Tretment Outcomes in Previously Untreted Ptients with Multiple Myelom: A Retrospective Anlysis from US Community Oncology Prctices Robert M
More informationBody mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health
Originl Article - Sexul Dysfunction/Infertility pissn 2005-6737 eissn 2005-6745 Body mss index, wist-to-hip rtio, nd metbolic syndrome s predictors of middle-ged men's helth Jung Hyun Prk *, In-Chng Cho
More informationTrends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
ORIGINAL ARTICLE Trends in ntihypertensive nd lipidlowering therpy in subjects with type II dibetes: clinicl effectiveness or clinicl discretion? MC Gulliford, J Chrlton nd R Ltinovic Deprtment of Public
More informationClinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini
More informationONCOLOGY LETTERS 14: , China Medical University, Shenyang, Liaoning , P.R. China
4890 Expression of vsculr endothelil growth fctor nd cspse 3 in mucinous brest crcinom nd infiltrting ductl crcinom not otherwise specified, nd the correltion with disese free survivl QIULI WANG 1, LISHA
More information